Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 23Gemcitabine 14Carboplatin 10Nivolumab 9Cyclophosphamide 9olaparib 8Specimen Handling 8Paclitaxel 8Trastuzumab 7Magnetic Resonance Spectroscopy 6fludarabine 5Standard of Care 5Irinotecan 5Ipilimumab 5Docetaxel 5Cisplatin 5Capecitabine 5Biopsy 5sargramostim 4pertuzumab 4palbociclib 4enzalutamide 4durvalumab 4atezolizumab 4aldesleukin 4Taxes 4Oxaliplatin 4Fluorouracil 4Erlotinib Hydrochloride 4Early Intervention, Educational 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Lactones × Genitourinary × Clear all
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡